For how we live.
An Ontario cohort of 1,035,927 pregnancies found excessive gestational weight gain was linked to more severe maternal morbidity in every BMI category, adjusted rate ratios 1.16 to 1.33 (observational).
An observational study of 8,127 UK women on GLP-1 drugs, almost all tirzepatide, reported 16.1 kg average loss at six months and 91.4% retention. There was no control arm.
In a 462-person phase 3 trial, a synthesised copy of semaglutide, HD1916, cut body weight 13.1% over 44 weeks against 14.4% for the branded drug — inside the margin set for calling them equivalent.
In the phase 3 SYNCHRONIZE-2 trial, the glucagon/GLP-1 dual agonist beat placebo on weight over 76 weeks. The effect was solid but smaller than the class leaders manage, and the maker funded it.
A population-linked Australian cohort followed children to school entry after antenatal metformin. The adjusted relative risk of developmental vulnerability was 0.97 — no different from unexposed children.
ZUPREME 1 tested a once-weekly amylin analogue that works differently from GLP-1 drugs, finding up to 9.4% weight loss at 28 weeks and gastrointestinal side-effects close to placebo. Zealand Pharma funded it.
In TRIUMPH-1, a triple hormone-receptor agonist produced a 25% average weight loss at the top dose over 80 weeks, and also eased knee pain and sleep apnoea. The trial was funded by Eli Lilly.
In a 76-woman randomised trial, a six-hour daily eating window and standard calorie restriction each produced about a 4% weight loss over six months, with no advantage for either approach.
In the LOSE-AF trial, an eight-month low-calorie programme cut weight by 9.7% in older adults with AF. It did not change their symptoms, their AF burden, or their need for further rhythm treatment.
A meta-analysis of 10 randomised trials found ultra-processed diets raised weight and eating rate, yet the effect on how much people ate mostly disappeared when diets were not more energy-dense.
A regional Global Burden of Disease analysis attributes 15.8 million healthy life-years lost in 2023 to high body-mass index, and warns of a 346.3% rise in obesity among the young.
Probably not ideal. Even moderate light during sleep measurably raises night-time heart rate and next-morning insulin resistance, and in one large study women who slept with a light or TV on gained more weight.
Visceral fat packed around the organs tends to be shed preferentially with modest weight loss. What lingers is subcutaneous fat — and you cannot choose where it comes off, which is what makes the belly feel stubborn.
You cannot burn fat off a specific area by exercising it. When researchers trained a single limb or drilled abdominal muscles for weeks, fat came off the body generally, not the spot being worked.
Short sleep is tied to obesity, and experiments suggest the link is partly causal. Adults told to sleep longer ate about 270 fewer calories a day; dieters who slept less lost far less of their weight as fat.
Barely, and some carry real risk. Caffeine has a small, measurable effect; the other headline 'thermogenic' ingredients mostly don't, and high-dose green tea extract has caused liver injury.
Losing weight lowers resting metabolism and keeps it low — Biggest Loser contestants ran hundreds of calories below baseline six years on. But that brake slows loss; it does not store fat.
The advice to lose weight slowly assumes fast loss is regained faster. Two randomised trials found the rate barely affects long-term regain — though rapid loss can cost more lean mass and carries its own risks.
No study shows that eating sugar worsens cancer, phones do not damage genes, and biopsies rarely spread it. A guide to what the National Cancer Institute actually concludes about the most persistent myths.
Obesity and metabolic syndrome push men's testosterone down. One large trial shows testosterone can cut new diabetes modestly, but the effect is smaller than weight loss and comes with safety trade-offs.
Across 23 cohort studies and 441,199 people, large weight fluctuation was linked to a 41% higher risk of death. Whether the cycling itself does harm, or reflects who cycles, the data cannot fully separate.
Chronic stress is linked to weight gain, and cortisol is one plausible route. But the measured associations are modest, and cortisol is a contributor, not the master switch that supplement marketing implies.
Told to cut fat or cut carbs, dieters in a 609-person Stanford trial lost 5.3 versus 6.0 kg over a year — a 0.7 kg gap. An 811-person trial agreed: the calorie deficit, not the macronutrient ratio, drives weight loss.
Observational studies disagree — evening looked best in adults with obesity, morning-to-midday in the wider population. None is a trial, and total activity dwarfs timing.
Randomised trials show a Palaeolithic diet trims weight and risk markers in the short term. A two-year trial found the early edge over an ordinary healthy diet had mostly faded — and that people struggled to stick to it.
A critical review went looking for clinical proof that commercial detox diets remove toxins or keep weight off. It found almost none, and no randomised trial of a commercial detox diet in humans at all.
A BMI over 30 flagged obesity in 19.1% of US men, but measured body fat found it in 43.9%. A 58-expert Lancet commission now says BMI alone should not diagnose obesity in an individual.
A 2025 meta-analysis of 10 trials found small, short-term reductions in weight and BMI — but the studies were heterogeneous, and the viral single trial that fuelled the hype is one small study, not a settled result.
The first randomised head-to-head trial of the two obesity drugs gave 751 adults the maximum tolerated dose of each for 72 weeks. Tirzepatide cut weight by 20.2%, semaglutide by 13.7%.
The line is marketing, not trial data. A meta-analysis of 13 randomised trials found adding breakfast raised daily calories and, if anything, nudged weight up, not down. A controlled feeding trial explains why.
Six years after 'The Biggest Loser', contestants had regained most of the weight — and their resting metabolism was still running 500 calories a day slower than expected. The diet triggers a defence that outlasts it.
An unplanned cheat day can erase a week's calorie deficit and has no trial support. Structured diet breaks are different — one trial found they improved weight loss, though another found no body-composition edge.
Amycretin, a single molecule that activates both the GLP-1 and amylin receptors, produced up to 24.3% weight loss over 36 weeks in a 125-person study. The primary goal, though, was safety — not weight.
In a company-funded randomised trial, adults who lost weight then took pasteurised Akkermansia muciniphila regained 1.2 kg over 24 weeks versus 3.2 kg on placebo — a modest effect in 90 people.
Scans confirmed that adults keep heat-producing brown fat, switched on by cold and linked to better metabolic health. Whether you can build enough of it to matter for weight is far less certain.
A meta-analysis of 11 trials put the change in a healthy man's resting testosterone from training at zero. Endurance work can lower it; losing body fat is the lever that reliably raises it.
In ESSENCE, the first 800 patients with biopsy-confirmed fatty-liver disease were analysed at week 72. Steatohepatitis resolved in 62.9% on semaglutide versus 34.3% on placebo — an interim look at an ongoing trial.
A new analysis of the REDEFINE 1 trial reframes obesity treatment around reaching a normal BMI and waist size, not just percentage lost. The combination beat semaglutide alone on that measure.
A retrospective analysis of 54,114 women on a digital weight-loss service found those with PCOS lost as much as those without. But only 40 PCOS users reached the 10-month mark, and the data are observational.
Two randomised trials found a 500 ml glass of water before meals adds a modest extra loss — about 1.3 kg over 12 weeks in one. The effect is real but small, short-term, and no substitute for the diet itself.
Whole fruit is linked to lower type 2 diabetes risk, sugary drinks to clearly higher risk, and fruit juice sits closer to the drinks than to the fruit it comes from.
A kilogram of muscle burns about 13 calories a day at rest — far less than the fitness-marketing figure implies. But resistance training does nudge resting metabolism up, by roughly 96 calories a day in a meta-analysis.
The main randomised trial found babies who fed themselves were no slimmer, no more iron-deficient and no more likely to choke than spoon-fed babies — provided parents were coached to offer safe, iron-rich foods.
A cohort of 5.24 million UK adults linked higher BMI to 17 of 22 cancers — strongly for the uterus, weakly or not at all for others, and inversely for a couple. The pattern is specific, not uniform.
A large study of energy use across the lifespan found it holds steady from age 20 to 60, once body size is accounted for. The midlife metabolic slump is mostly a myth; the decline comes later.
Head-to-head randomised trials find low-carbohydrate and low-fat diets produce similar weight loss over a year or two. The differences that survive are in blood lipids and glycemic control, not the scale.
Substantial, sustained weight loss can return blood sugar to the normal range without drugs in some people diagnosed recently. It is real, it is not a cure, and it fades as the weight comes back.
MariTide antagonises the GIP receptor that tirzepatide switches on, yet in 592 adults it drove 12–16% weight loss over a year — and it is dosed once a month, not once a week.
A transcriptomic sub-study of the CALERIE calorie-restriction trial links 151 genes to preserved leg strength during weight loss, independent of how much body mass was lost.
Applied to 411,000 UK Biobank adults, the Edmonton staging system and the Lancet Commission's clinical-obesity model classified severe disease alike but diverged on who counts as early-stage.
In 2.5 million Swedish births followed to adulthood, mothers' early-pregnancy obesity was linked to a stepwise rise in offspring cardiovascular disease, though sibling analyses temper the size.
Intensive family-based behavioural programmes produce small, real cuts in children's BMI; the newer weight-loss drugs produce much larger ones, but the weight returns when they stop.
An updated Annals review now covers 38 randomised trials and 25,816 people. Tirzepatide leads the marketed drugs at 19.0% placebo-subtracted weight loss; the experimental multiagonists run higher.
The association was strongest where the air was worst — which is the tell. A parallel US survey finds the indoor facilities are the ones vanishing from low-income neighbourhoods.
A matched study compared recreational runners, non-runners and adults with obesity, one triplet at a time. The first two groups were indistinguishable on structure and function. The third was not.
A tightly controlled crossover trial found late eating increased hunger, cut waking energy expenditure and shifted fat-tissue gene expression. The population data show a 17% higher odds of obesity.
A Lancet review triangulates the evidence linking adiposity to multisystem disease and finds robust trial support in a short list — while an expert panel argues the drugs must be lifelong.
A study estimated semaglutide's class could be produced for under $75 a month; it lists near $1,000. The gap is patent protection, and in the US it runs to 2032.
National surveys show risk behaviours climbing among adults with diabetes since 2007, while a separate study finds noncommunicable-disease mortality nearly twice as high in the worst-affected province as in the best.
A supplement approved on 26 August adds SURPASS-CVOT to the prescribing information and rewrites the eye warning so it is addressed to patients with a history of retinopathy rather than to patients with diabetes.
A 4,066-person survey series across Funafuti and the outer islands links second-hand smoke exposure — reported by 61% of participants — to obesity and elevated STOP-Bang scores.
The glucagon and GLP-1 dual agonist, already approved in China, cut bodyweight 18.1% at 16 mg and 15.6% at 10 mg over 32 weeks versus 0.9% on placebo in a US phase 2 trial.
A meta-analysis of 116 randomised trials found weight, waist and body fat falling steadily up to 300 minutes a week. In one 24-week trial, 48% of participants compensated by about 308 kcal a day.
PBAC recommended subsidized listing in November 2025 for adults with obesity and a history of heart attack or stroke. Price negotiations with Novo Nordisk had not concluded.
Pooled randomised data show incretin drugs shed lean mass in about the same proportion as lifestyle weight loss. The evidence gap is people who train seriously, and it has not been filled.
Tirzepatide has been approved for obstructive sleep apnea since December 2024. A January 2026 reanalysis of the trial behind that approval separates what weight loss fixed from what treating the breathing fixed.
Pooling 32 trials, researchers found milk, whey, casein, and soy protein lowered LDL and total cholesterol slightly — but the effect shrank once weaker studies were excluded.
Mice lacking the chaperone GRPEL2 stayed leaner on a high-fat diet and kept better insulin sensitivity — an early mechanistic finding, not a treatment, and so far only in mice.
Heavy drinking tracks with weight gain fairly consistently. For light-to-moderate drinking, the evidence is genuinely mixed — and confounded by who drinks that way.
New GBD analysis across 21 countries finds one group whose burden fell — children — while incidence rose 92% overall and the sex pattern inverted.
Orforglipron removes the injection from weight-loss medicine — a real change for people who refused one. Supply, cost, and coverage are the harder problems it does not solve.
An umbrella review graded 249 effect sizes across 67 risk factors for male infertility. More than half were rated very low certainty — and the review contradicts its own table on one of them.
Applying the clinical-versus-preclinical obesity framework to 2,316 surgical patients in four countries found two groups near-identical on BMI and different on almost everything else.
Two WHO bodies reported on the same day in July 2023 and reached findings that sound contradictory. Both were right, because they were answering different questions.
Pooling 13 randomised trials, people assigned to eat breakfast ended up 0.44 kg heavier and ate 260 more calories a day than people assigned to skip it. The trials were small, short and mostly low quality.
A 2026 meta-analysis of 19 trials found training at maximal fat-oxidation intensity cut body weight by 3.66 kg. Head-to-head trials against interval training find no consistent winner on body fat.
GLORY-2 randomised 461 Chinese adults with obesity to a weekly GLP-1/glucagon dual agonist or placebo; weight fell 16.65% versus 1.50% at 60 weeks, alongside high rates of nausea and vomiting.
In February, FDA said it intended to act against compounded GLP-1 supply without saying how. The answer arrived in May: exclude semaglutide, tirzepatide and liraglutide from the list.
Four separate trial emulations, each with a different comparator, all pointed the same direction. The strongest effect appeared among people being treated for alcohol use disorder.
Petrelintide, a long-acting amylin analogue given without a GLP-1 drug, reduced bodyweight by up to 8.6% at 16 weeks across two small phase 1 trials and was well tolerated. The finding is early.
Tirzepatide topped weight loss at 14.9%. But only subcutaneous semaglutide showed a mortality benefit — and no drug moved the needle on quality of life or kidney failure.
Tirzepatide and semaglutide showed comparable psychiatric risk profiles against each other over two years. Against earlier GLP-1 drugs, semaglutide came out ahead on all three measures.
A Global Burden of Disease comparison puts the 2023 US maternal mortality rate at 33.8 per 100,000 live births, alongside cardio-kidney-metabolic risk burdens several times those of other high-income countries.
A Swiss cohort was classified by WHO, NIH and EASO criteria at the same time. The share of people with obesity roughly doubled, and the overweight category shrank to fill the gap.
Gastric bypass patients lost roughly 28% of body weight at three years, against 7-11% for tirzepatide or semaglutide — even among patients who stayed on the drugs continuously for at least a year.
Lilly's oral GLP-1 pill actually lowered liver enzymes on average, and its rate of serious liver-injury criteria matched placebo exactly — six cases in each group, none attributable to the drug.
Pooled across 23 trials, weight-loss apps beat a waitlist by about 2 kg at six months. Which features the app had made no measurable difference; adherence, which falls over time, is the real variable.
Pooling 2,906 participants, researchers ranked how antidiabetic drugs affect fat versus lean body mass. Exercise blunted liraglutide's muscle loss; metformin, insulin, and DPP4 inhibitors barely moved either measure.
SYNCHRONIZE-MASLD reports 84.2% of survodutide patients hitting a 30% cut in liver fat at 48 weeks. The trial measured fat on MRI, not fibrosis on biopsy — which is where the harder question still sits.
In TRANSCEND-T2D-1, the triple-hormone agonist cut HbA1c up to 1.12 points beyond placebo over 40 weeks and trimmed bodyweight 15.3% at the top dose in early type 2 diabetes.
The association held across most demographic subgroups, but not among Black patients, a gap the study doesn't explain. Two-year follow-up limits what it can say about longer-term risk.
Pooling a decade of research on women with hypertension, diabetes and obesity, researchers found modest blood pressure and metabolic shifts only in select high-risk subgroups.
The ESC Atlas reports 68 million disability-adjusted life years and more than three million cardiovascular deaths a year, with middle-income countries carrying roughly double the mortality of high-income ones.
In 38,283 nurses tracked through the transition, low-insulinemic and planetary-health eating patterns had the strongest associations with less weight gain. The average woman still gained 0.8 kg a year.
A five-year FAERS analysis found both semaglutide and tirzepatide carry disproportionate ketoacidosis signals in people without diabetes, with roughly three-quarters of reported cases requiring hospitalization.
ATTAIN-MAINTAIN tested orforglipron as a maintenance therapy for people who'd already lost weight on tirzepatide or semaglutide. Those on placebo regained roughly half of what the pill preserved.
A Qatar Biobank analysis derived local cut-points and found WHO's standard numbers misclassified more than half of men and nearly half of women in the sample.
No study has directly compared injectable tirzepatide with the new high-dose oral semaglutide pill. A statistical technique that adjusts across two separate trials estimates the gap.
Pooling 24 studies out of 133 screened, researchers found hair shedding tied to rapid weight loss more than to the drugs directly — and a pattern that hits women disproportionately.
The LiverScreen project ran transient elastography across nine countries, then sent everyone who screened positive to a hepatologist. The gap between the two numbers is the interesting part.
Two 2026 reviews describe the same handover: as the virus recedes, obesity-driven fatty liver disease is moving into the space it occupied — in a population where roughly 40% of screened adults met obesity criteria.
A single-clinic retrospective study in Istanbul followed patients on all three drugs for 36 weeks. The ranking matches what randomized trials have shown — with liraglutide the least tolerated of the three.
In 3,873 middle-aged adults followed with repeated testing, waist-based categories of overweight and obesity showed larger effect sizes than BMI-based ones. The link to actual decline appeared only in men.
OCULUS was halted at interim analysis: continuing a GLP-1 or GIP agonist before endoscopy left 25.0% of patients with clinically significant retained stomach contents, versus 3.1% who held one dose.
A survey-based analysis of the European Health Interview Survey puts a price on Europe's obesity-related hospital use, and finds the strongest single association is not with obesity at all.
Sequencing 6,141 people turned high consanguinity into a research advantage: it produced natural human knockouts that population studies elsewhere almost never see.
Bimagrumab targets fat, not appetite. Paired with semaglutide in 507 adults with obesity, the combination out-performed either drug alone at 48 weeks — with its own separate set of side effects.
ACHIEVE-3 randomised 1,698 people to orforglipron or oral semaglutide for 52 weeks. Orforglipron cut HbA1c more at every dose comparison — and produced more side effects and more dropouts.
A 444,000-patient records study found a two-thirds lower rate of endometrial cancer when GLP-1 receptor agonists were added to progestin therapy. The two groups differed by eight years in average age.
A Lancet study across 547,000 adults and 925 infectious diseases finds obesity raises the risk of severe infection across almost every pathogen type. The global estimate rests on modelling, not on the cohorts themselves.
The agency announced an intent to restrict GLP-1 active ingredients destined for non-approved compounded drugs, and warned that seizure and injunction are on the table without further notice.
In a 618-person randomized trial, 27.8% of the intervention group met the sustained-remission endpoint at 24 months against 21.2% of comparators. The confidence interval nearly touches no effect.
Large taxed beverage sales fell 24 to 31 percent under the tax. In the period after repeal they remained 13 to 24 percent below pre-tax levels — and prices stayed elevated too.
An Oxford meta-analysis of 37 studies puts average regain at 0.4 kg a month across all weight-management drugs, and 0.8 kg a month for semaglutide and tirzepatide. Almost none of the newer-drug data runs past a year.
The 2025–2030 edition was released January 7. It is the first to name highly processed foods, and the first whose saturated-fat arithmetic does not obviously close.
On the unprocessed diet, participants built plates 57% heavier and 110 calories lighter. The authors argue that fruit and vegetables were crowding out calories on purpose.
Matched against a comparator diabetes drug, incretin agonists were associated with an 8% lower rate of CPAP procedures — alongside a 32% lower mortality that should make readers cautious.
FDA cleared oral semaglutide 25 mg on 22 December for chronic weight management and cardiovascular risk reduction. Its self-pay price, not its efficacy, is what may distinguish it.
The headline finding is noninferiority. The more useful finding is what the shared denominator was — and how wide a gap the trial was designed to tolerate.
TRIUMPH-4 tested retatrutide in 445 adults with obesity and knee osteoarthritis. The weight numbers are striking. So are the discontinuation numbers sitting beside them.
The ADA's 2026 Standards of Care add guidance on individualising obesity-drug dosing, name two eating patterns for type 2 diabetes prevention, and recommend continuous glucose monitoring from diagnosis.
The recommendations are conditional, cover three drugs, and come with a projection that fewer than one in ten people who could benefit will have access by 2030.
Two November burden analyses put diabetes diagnosed before 40 on an upward path to 2050. In the Americas, Central Latin America carried the highest rates and men carried more of the burden than women.
Nearly a million conscripts followed for three decades: obesity carried a 3.1-fold hazard for sepsis, and high cardiorespiratory fitness was associated with a 42% lower risk of dying from bacterial infection.
In ATTAIN-2, the highest dose of the oral GLP-1 pill cut body weight 9.6% over 72 weeks in adults with type 2 diabetes, against 11.2% in the earlier trial of adults without diabetes.
Three papers published on 18 November argue the harm is not one ingredient but the replacement of whole-food diets. The evidence they assemble is strongest for diet quality and weakest where causation is hardest.
Head-to-head in US insurance data, the two drugs showed comparable cardiovascular outcomes and comparable rates of severe gastrointestinal events in type 2 diabetes. Neither study was a trial.
Among 1,000 adults in Mwanza, overnight oximetry found sleep apnea in 17% of people with HIV and 19% without. Excessive daytime sleepiness, oddly, was more common in those without HIV.
Carriers of loss-of-function MC4R mutations had lower LDL and triglycerides than UK Biobank controls of similar adiposity, and lower cardiovascular risk. The brain sets body weight and lipids separately.
Two phase 3b trials tested semaglutide 7.2 mg against the approved 2.4 mg dose. The extra weight loss was real but modest, and gastrointestinal side-effects and dysaesthesia rose alongside it.
A French prospective cohort followed adults with rare genetic obesity treated with the MC4R agonist in routine care. Weight fell about 20% in the first year and hunger scores dropped 62%.
A Spanish trial in 4,746 adults compared an energy-reduced Mediterranean diet plus exercise against the same diet eaten freely. Over six years the absolute gap was 12.0% versus 9.5%.
Fifty-five English adults ate two eight-week diets that both followed the UK Eatwell Guide. Both produced weight loss. The minimally processed version produced about one percentage point more.
A meta-analysis of pedometer, tracker and smartwatch interventions lasting 12 to 48 weeks found no significant change in systolic or diastolic pressure — nor in weight, glucose or HbA1c.
The proposed Nutrition Info box would rate saturated fat, sodium and added sugars on the front of most packaged foods. The strongest real-world evidence is for blunter warning labels.
A BMJ network meta-analysis of 6,582 adults finds alternate day fasting the only intermittent method that beat continuous calorie restriction — by 1.29 kg, mostly in short trials.